Key Highlights

  • Audeara Limited (ASX:AUA) has formally commenced the process to establish a US OTCID Quotation to broaden potential access for US investors.
  • US-based Viriathus Capital LLC Series has been appointed as non-exclusive Financial Advisor for an initial three-month engagement to lead the quotation process.
  • The move follows record FY26 Group Revenue of approximately $4.45 million, including approximately $1.56 million from North America.
  • No capital raising or new securities are proposed as part of the OTCID quotation process, meaning existing shareholders are not diluted.

Audeara Limited (ASX:AUA) share price jumped 17.39% on Tuesday. Recently, the company announced that it has formally commenced the process to establish quotation of its ASX-listed ordinary shares on the OTCID tier of the US Over-the-Counter market. As part of the process, the Company has appointed US-based Viriathus Capital LLC Series as its non-exclusive Financial Advisor for an initial three-month engagement, with Viriathus to manage the OTCID quotation process including eligibility review, preparation of the application, liaison with OTC Markets Group and the relevant market maker, and ongoing quotation requirements.

The Company stated that the ASX remains its primary listing and home market, while the proposed OTCID quotation is designed to provide US-based investors with a more familiar and accessible pathway to trade Audeara securities. Importantly, the proposed quotation does not involve a capital raising or the issue of new securities, meaning the initiative is designed to broaden potential investor access without diluting existing shareholders. Quotation remains subject to completion of the application process, eligibility review and acceptance by OTC Markets, with no guarantee that quotation will be approved, and Audeara noting it will update the market if and when quotation is approved and trading is able to commence. The Company indicated the proposed listing is expected within six to eight weeks.

Record FY26 Financial Performance

The listing expansion follows a year of record Group revenue for Audeara. FY26 revenue increased to approximately $4.45 million, including approximately $1.56 million generated from North America. AUA Technology contributed approximately $1.68 million in revenue during FY26, and the Company noted that the first two OPTEK customer programs incorporating its proprietary AI audio technology had progressed to commercial production.

The Company described these developments as reinforcing its position at the convergence of hearing health, connected hardware, embedded software and AI-enabled audio processing, stating that this growing commercial validation strengthens the rationale for broadening access to Audeara among United States technology and healthcare investors.

Rationale for the OTC Quotation

Audeara stated the initiative complements its existing commercial activities in North America and its growing international profile. The Company noted that North America is already an important commercial market, and that broadening access to US technology and healthcare investors represents what it characterised as a logical next step in its development, with the ASX remaining its home market.

Management Commentary

Audeara CEO Dr James Fielding said FY26 was an important year for the Company, noting it delivered record revenue, materially improved operating cash flow, and saw its technology increasingly move from development into commercial deployment. He said the Business has evolved beyond selling audio hardware to now operate across hearing health, connected devices, embedded software and AI-enabled audio processing.

Fielding said this combination creates what he described as an increasingly compelling technology story, with North America already an important commercial market for the Company. He said broadening access to the Company for US technology and healthcare investors is therefore a logical next step, with the ASX remaining the Company's home market while an OTC quotation offers the opportunity to build a wider international investor audience without issuing new shares as part of the quotation process.

Conclusion

Audeara has moved to broaden its investor base in the United States through a proposed OTCID quotation that would sit alongside its existing ASX listing, a step the Company has linked to record FY26 revenue and growing commercial traction across its hearing health, AI audio and connected device offerings. With Viriathus Capital engaged to manage the quotation process and no new securities proposed as part of the initiative, the Company's approach is structured to extend investor access without affecting existing shareholders' proportional ownership, subject to the standard OTC Markets eligibility review and acceptance process.